Trouillas P, Moindrot J, Betuel H, Quincy C, Aimard G, Devic M
Rev Neurol (Paris). 1976 Oct;132(10):684-704.
The authors describe the results of immunological assay of complement factors C3, C4 (the usual path of activation of complement) and of B factor (the alternate path of activation) in 61 multiple sclerosis patients not receiving corticoids, 52 normal controls and 217 patients with other neurological disorders. Hypocomplementaemia (fall in factor C3 related to a fall in total haemolytic activity) was found in 29.5 p. 100 of the patients not on corticotherapy at the first assay, and in 36 p. 100 of the patients when repeated assays were carried out. Hypocomplementaemia is significantly more frequent in multiple sclerosis than in the normal population (0 p. 100) and in neurological patients (9.6 p. 100). In 13.1 p. 100 of the multiple sclerosis patients there was a decrease in B factor: 50.3 p. 100 of the multiple sclerosis patients exhibited no quantitative abnormality of the main factors of complement (normocomplementary multiple sclerosis). The group of multiple sclerosis patients with hypocomplementaemia was characterized by the incidence of other abnormalities in the complement system: cleavage of the C3 factor and a fall in B factor in 60 p. 100 of the cases. A more frequent increase in IgE and measles antibodies was found also while the normocomplementary multiple sclerosis patients more frequently had higher levels of IgA. Genetically, the group with hypocomplementaemia is related to a significant increase in the incidence of the HL-A W18 group while the normocomplementary multiple sclerosis patients appear closely related to the HL-A7 group. Familial investigations show that hypocomplementaemia is usually present in the ascendents and collaterals and that it seems to be transmitted with the HL-A haplotypes. Four families gave evidence of transmission with the W18 group. This transmission sometimes occurs together with transmission of an increase in IgE and/or of measles antibodies. In two pedigrees, one of the ascendents carried in his serum an activator of the alternate path of complement. There does not appear to be any prognostic difference between the two groups. In multiple sclerosis with hypocomplementaemia, the facts suggest a complex immunological abnormality, transmitted genetically to the subject and existing prior to the illness, comprising both elements of deficient and excessive immune response. The recognized presence of a gene of immunological reactivity and of genes of synthesis of complement on the 6th chromosome, in proximity with genes of histocompatability (HL-A and M.L.C.) provides a theoretical basis for this supposition.
作者描述了对61例未接受皮质类固醇治疗的多发性硬化症患者、52例正常对照者以及217例患有其他神经系统疾病的患者进行补体因子C3、C4(补体激活的经典途径)和B因子(补体激活的替代途径)免疫测定的结果。在首次检测时,29.5%未接受皮质类固醇治疗的患者出现低补体血症(C3因子下降与总溶血活性下降相关),重复检测时这一比例为36%。多发性硬化症患者中低补体血症的发生率显著高于正常人群(0%)和神经系统疾病患者(9.6%)。13.1%的多发性硬化症患者B因子下降:50.3%的多发性硬化症患者补体主要因子无定量异常(正常补体性多发性硬化症)。低补体血症的多发性硬化症患者组的特点是补体系统存在其他异常:60%的病例中C3因子裂解和B因子下降。同时还发现低补体血症组中IgE和麻疹抗体更频繁升高,而正常补体性多发性硬化症患者IgA水平更高。从遗传学角度来看,低补体血症组与HL - A W18组发生率显著增加有关,而正常补体性多发性硬化症患者似乎与HL - A7组密切相关。家族研究表明,低补体血症通常存在于先辈和旁系亲属中,且似乎与HL - A单倍型一起遗传。四个家族证明了与W18组的遗传传递。这种传递有时与IgE和/或麻疹抗体升高的传递同时发生。在两个家系中,一位先辈血清中携带补体替代途径的激活剂。两组之间似乎没有任何预后差异。在低补体血症的多发性硬化症中,这些事实表明存在一种复杂的免疫异常,遗传传递给个体且在疾病发生前就已存在,包括免疫反应不足和过度的因素。在第6号染色体上已确认存在免疫反应基因和补体合成基因,与组织相容性基因(HL - A和M.L.C.)相邻,这为该假设提供了理论基础。